Ascentage Pharma Group In... (AAPG)
NASDAQ: AAPG
· Real-Time Price · USD
42.64
-0.84 (-1.93%)
At close: Aug 26, 2025, 3:59 PM
43.30
1.54%
After-hours: Aug 26, 2025, 07:14 PM EDT
Ascentage Pharma International Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 1.24B | 1.26B | 1.1B | 1.1B | 1.07B | 1.09B | 1.58B | 1.48B | 1.7B | 1.71B | 1.1B |
Short-Term Investments | n/a | 5.37M | n/a | n/a | n/a | 6.56M | n/a | n/a | n/a | n/a | 428.7M |
Long-Term Investments | 33.86M | 33.86M | n/a | 33.2M | 18.95M | 18.95M | n/a | 18.53M | n/a | n/a | n/a |
Other Long-Term Assets | 59M | 103.54M | 52.5M | 74.37M | 10.05M | 70.06M | 368.64M | 361.93M | 38.84M | 63.73M | 105.05M |
Receivables | 99.07M | 83.14M | 852.81M | 743.52M | 163.54M | 145.89M | 174.22M | 61.49M | 161.5M | 54.13M | 66.34M |
Inventory | 6.6M | 6.6M | 10.72M | 10.72M | 16.17M | 16.17M | 5.02M | 9.45M | 5.25M | 3.93M | n/a |
Other Current Assets | 24.63M | 117.84M | n/a | 109.29M | 24.54M | 81.73M | n/a | 16.6M | -80.83M | 59.26M | -56M |
Total Current Assets | 1.47B | 1.47B | 1.96B | 1.96B | 1.34B | 1.34B | 1.76B | 1.64B | 1.87B | 1.89B | 1.6B |
Property-Plant & Equipment | 905.86M | 905.56M | 931.18M | 931.18M | 957.23M | 957.07M | 633.06M | 650.02M | 968.46M | 854.3M | 616.64M |
Goodwill & Intangibles | 100.69M | 100.69M | 104.47M | 104.47M | 110.14M | 110.14M | 104.8M | 109M | 115.53M | 85.11M | 88.47M |
Total Long-Term Assets | 1.14B | 1.14B | 1.14B | 1.14B | 1.16B | 1.16B | 1.16B | 1.19B | 1.17B | 1.05B | 810.15M |
Total Assets | 2.62B | 2.62B | 3.11B | 3.11B | 2.5B | 2.5B | 2.92B | 2.83B | 3.03B | 2.94B | 2.41B |
Account Payables | 91.97M | 91.97M | 83.08M | 83.08M | 72.44M | 72.44M | 47.72M | 95.56M | 85.73M | 70.86M | 28.4M |
Deferred Revenue | 54.09M | n/a | n/a | n/a | 38.41M | n/a | n/a | 24.35M | n/a | n/a | n/a |
Short-Term Debt | 769.62M | 769.62M | 720.1M | 720.1M | 606.65M | 606.65M | 396M | 510.31M | 298.93M | 39.8M | 23.95M |
Other Current Liabilities | n/a | 142.25M | 37.48M | 112.49M | n/a | 119.64M | 24.35M | 2.82M | 30M | 58.73M | 25K |
Total Current Liabilities | 1.17B | 1.17B | 1.07B | 1.07B | 934.17M | 934.17M | 642.88M | 881.15M | 612.3M | 361.11M | 193.79M |
Long-Term Debt | 868.64M | 868.64M | 959.14M | 959.14M | 1.17B | 1.17B | 1.26B | 1.27B | 1.24B | 1.03B | 622.54M |
Other Long-Term Liabilities | 6.27M | 287.6M | 18.8M | 294.73M | 18.3M | 316.4M | 185.31M | 35.33M | 52.63M | 52.34M | 75.97M |
Total Long-Term Liabilities | 1.18B | 1.18B | 1.27B | 1.27B | 1.5B | 1.5B | 1.68B | 1.54B | 1.55B | 1.34B | 764.52M |
Total Liabilities | 2.34B | 2.34B | 2.33B | 2.33B | 2.43B | 2.43B | 2.32B | 2.42B | 2.16B | 1.71B | 958.31M |
Total Debt | 1.67B | 1.67B | 1.7B | 1.7B | 1.8B | 1.8B | 1.68B | 1.79B | 1.56B | 1.08B | 667.41M |
Common Stock | 214K | 214K | 214K | 214K | 197K | 197K | 196K | 180K | 179K | 178K | 172K |
Retained Earnings | -5.77B | -5.77B | -5.2B | -5.2B | -5.37B | -5.37B | -4.84B | -4.44B | n/a | -3.56B | n/a |
Comprehensive Income | -510.59M | -510.59M | n/a | -501.79M | -504.46M | -504.46M | n/a | -518.51M | n/a | n/a | n/a |
Shareholders Equity | 264.19M | 264.19M | 766.4M | 766.4M | 60.42M | 60.42M | 589.89M | 408.66M | 876.85M | 1.23B | 1.45B |
Total Investments | 33.86M | 39.23M | 33.2M | 33.2M | 18.95M | 25.51M | 18.66M | 18.53M | 21.1M | 27.84M | 29.86M |